Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SFDA Penalizes Wandashan Pharmaceutical

This article was originally published in PharmAsia News

Executive Summary

China's State FDA released its latest report on the lethal Ciwujia herbal injection produced by Wandashan Pharmaceutical, concluding that the incident is a severe adverse reaction caused by bacteria. According to investigation, the particular batch of Ciwujia was soaked by rain water leading to contamination, but the company's sales person in Yunnan changed the packaging labels and sold the product. SFDA concluded that Wandashan Pharmaceutical violated the Drug Administration Law and demanded the Heilongjiang FDA to suspend the company's production and withdraw its GMP authentication. Furthermore, Wandashan Pharmaceutical will be penalized in accordance with the relevant laws. Personnel responsible for the incident will be banned from drug production and distribution for 10 years. (Click here for more - Chinese Language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC067120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel